Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Merck (NYSE: MRK) has announced its acquisition of Acceleron Pharma (NASDAQ: XLRN) for $180 per share, totaling approximately $11.5 billion. This strategic move aims to enhance Merck's cardiovascular pipeline, particularly with the integration of sotatercept, a promising therapy in Phase 3 development for pulmonary arterial hypertension (PAH). The deal underscores Merck's commitment to sustainable growth and innovation in treating cardiovascular diseases and is expected to close in Q4 2021.
Merck (NYSE: MRK) has appointed Thomas H. Glocer as independent lead director of its Board of Directors, effective immediately. Mr. Glocer, who joined the board in 2007, brings extensive expertise in management and international business, having previously served as CEO of Thomson Reuters. CEO Rob Davis praised Glocer’s valuable contributions and looks forward to their continued collaboration. Merck has a long-standing commitment to advancing health care through innovative medicines and vaccines, positioning itself as a leader in biopharmaceutical research.
Merck (NYSE: MRK) will host its third-quarter 2021 sales and earnings call on October 28 at 8:00 a.m. EDT. This event will provide an overview of the company’s quarterly performance and future outlook. Investors can listen to the call via a live webcast on Merck's website, with a replay available afterward. Merck has a longstanding commitment to developing innovative medicines and vaccines, focusing on diseases like cancer and infectious diseases. For more details, visit Merck’s investor relations page.
Merck (NYSE: MRK) announced the Phase 3 KEYNOTE-394 study results, where KEYTRUDA, its anti-PD-1 therapy, demonstrated a statistically significant improvement in overall survival (OS) for Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib. The study also achieved key secondary endpoints: progression-free survival (PFS) and objective response rate (ORR). No new safety concerns were reported. Merck is advancing research in HCC through a global program involving approximately 3,000 patients across multiple clinical trials.
Merck (NYSE:MRK) and AstraZeneca announced positive results from the Phase 3 PROpel trial, indicating that LYNPARZA combined with abiraterone/prednisone significantly improves radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC). The findings suggest potential first-line treatment options regardless of biomarker status. Although overall survival data remain immature, the trial's interim analysis showed an encouraging trend. The safety profile aligns with existing treatments, and further data will be presented at a medical meeting.
Merck (NYSE: MRK) announced significant results from the Phase 3 KEYNOTE-355 trial, showcasing KEYTRUDA's effectiveness in combination with chemotherapy for metastatic triple-negative breast cancer (mTNBC). The study revealed a 27% reduction in the risk of death, with an increased median overall survival of 6.9 months (23.0 months vs. 16.1 months) for patients expressing PD-L1 (CPS ≥10). This pivotal trial confirms KEYTRUDA's role in improving treatment outcomes for mTNBC, further supported by prior improvements in progression-free survival. Regulatory approvals are underway in both the U.S. and Europe.
Merck (NYSE: MRK) announced promising results from the Phase 3 KEYNOTE-716 trial, showing that KEYTRUDA reduced the risk of disease recurrence or death by 35% in patients with resected high-risk stage II melanoma compared to placebo. This marks the first anti-PD-1 therapy to improve recurrence-free survival (RFS) in this setting. After 14.4 months, 11.1% of KEYTRUDA patients experienced recurrence or death versus 16.8% in the placebo group. The FDA has accepted these findings for priority review, indicating potential for new treatment options for a high-risk patient population.
Merck (NYSE: MRK) announced positive results from the Phase 3 KEYNOTE-826 trial for KEYTRUDA, its anti-PD-1 therapy, in treating persistent, recurrent, or metastatic cervical cancer. The results were presented at the ESMO Congress 2021 and published in the New England Journal of Medicine. KEYTRUDA combined with chemotherapy showed a 33% reduction in mortality (median OS: 24.4 months vs. 16.5 months) and improved progression-free survival (PFS) at 10.4 months versus 8.2 months. KEYTRUDA also demonstrated a 65.9% overall response rate (ORR), marking it as the first anti-PD-1/PD-L1 regimen to show such improvements in this setting.
Merck (NYSE: MRK) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended KEYTRUDA, its anti-PD-1 therapy, for treating locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults with PD-L1 expression (CPS ≥10) who haven't had prior chemotherapy for metastatic disease. This recommendation is based on positive results from the Phase 3 KEYNOTE-355 trial, which showed significant improvements in progression-free survival and overall survival when KEYTRUDA is combined with chemotherapy. Approval is pending a review by the European Commission.
Merck (NYSE: MRK) announced key data from its oncology research program to be presented at the ESMO Congress 2021, occurring from Sept. 16–21. The highlights include Phase 3 results for KEYTRUDA in stage II melanoma (KEYNOTE-716) and metastatic cervical cancer (KEYNOTE-826), both chosen for the ESMO Presidential Symposium. These trials showed significant improvements in recurrence-free and overall survival, respectively. Merck is committed to advancing treatments for challenging cancers, with a focus on collaborative research for better patient outcomes.